KR890000093A - 건선의 치료방법 및 치료용 조성물 - Google Patents

건선의 치료방법 및 치료용 조성물 Download PDF

Info

Publication number
KR890000093A
KR890000093A KR1019880006883A KR880006883A KR890000093A KR 890000093 A KR890000093 A KR 890000093A KR 1019880006883 A KR1019880006883 A KR 1019880006883A KR 880006883 A KR880006883 A KR 880006883A KR 890000093 A KR890000093 A KR 890000093A
Authority
KR
South Korea
Prior art keywords
azidothymidine
medicament
topical
composition
use according
Prior art date
Application number
KR1019880006883A
Other languages
English (en)
Other versions
KR950014447B1 (ko
Inventor
두빅 마들레인
더블유·브류톤 게리
Original Assignee
한스 마크
보오드 오브 레전츠, 더 유니버시티 오브 텍사스 시스템
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한스 마크, 보오드 오브 레전츠, 더 유니버시티 오브 텍사스 시스템 filed Critical 한스 마크
Publication of KR890000093A publication Critical patent/KR890000093A/ko
Application granted granted Critical
Publication of KR950014447B1 publication Critical patent/KR950014447B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
    • A61K35/04—Tars; Bitumens; Mineral oils; Ammonium bituminosulfonate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

내용 없음

Description

건선의 치료방법 및 치료용 조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (13)

  1. 건선 치료용 약제 제조에 있어서의 아지도티미딘의 용도.
  2. 제1항에 있어서, 약제가 경구 토여 제제인 용도.
  3. 제2항에 있어서, 약제가 약 400 내지 2000mg 아지도티미딘/ 일로 경구토여할 수 있는 양의 아지도티미딘을 함유하는 용도.
  4. 제1항에 있어서, 약제가 비경구 투여 제제인 용도.
  5. 제4항에 있어서, 약제가 약 100 내지 2000mg인 아지도티미딘/ 일로 비경구 투여할 수 있는 양의 아지도티미딘을 함유하는 용도.
  6. 제1항에 있어서, 약제가 국소 투여 제제인 용도.
  7. 제6항에 있어서, 국소투여 제제가 약 0.25 내지 10%농도의 아지도티미딘을 함유하는 용도.
  8. 제7항에 있어서, 국소 투여 제제가 약 1내지 5%농도의 아지도티미딘을 함유하는 용도.
  9. 고약, 크림, 연고, 로숀, 페이스트 또는 겔로부터 선택된, 약학적으로 허용되는 국소투여 제제로 아지도티미딘을 함유하는 약학 조성물.
  10. 제9항에 있어서, 국소투여제제가 약 0.25 내지 10% 아지도 티미딘을 함유하는 조성물.
  11. 제10항에 있어서, 국소투여 제제가 1 내지 약 5% 아지도 티미딘을 함유하는 조성물.
  12. 제9항에 있어서, 유효량의 코르티코스테로이드 또는 피부표면-작용 건선치료제를 또한 함유하는 조성물.
  13. 제9항에 있어서, 피부표면-작용 건선치료제가 치환된 페놀, 타르, 황, 이크탐몰, 크레졸 또는 안트랄린인 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019880006883A 1987-06-09 1988-06-09 유효 성분으로 아지도티미딘을 함유하는 건선 치료용 약제 KR950014447B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/059,907 US4804651A (en) 1987-06-09 1987-06-09 Methods and compositions for the treatment of psoriasis
US059,907 1987-06-09

Publications (2)

Publication Number Publication Date
KR890000093A true KR890000093A (ko) 1989-03-11
KR950014447B1 KR950014447B1 (ko) 1995-11-28

Family

ID=22026060

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019880006883A KR950014447B1 (ko) 1987-06-09 1988-06-09 유효 성분으로 아지도티미딘을 함유하는 건선 치료용 약제

Country Status (15)

Country Link
US (1) US4804651A (ko)
EP (1) EP0301206B1 (ko)
JP (1) JP2510675B2 (ko)
KR (1) KR950014447B1 (ko)
AT (1) ATE71301T1 (ko)
AU (1) AU606423B2 (ko)
DE (1) DE3867560D1 (ko)
DK (1) DK310188A (ko)
ES (1) ES2038716T3 (ko)
GR (1) GR3003785T3 (ko)
HU (1) HU200693B (ko)
IE (1) IE61091B1 (ko)
MY (1) MY103734A (ko)
PH (1) PH26517A (ko)
ZA (1) ZA884056B (ko)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5527779A (en) * 1988-03-23 1996-06-18 Top Gold Pty Limited Topically applied gold organic complex
JPH0618777B2 (ja) * 1988-05-27 1994-03-16 アメリカ合衆国 精神神経性欠損症の治療に用いられる組成物
US5098899A (en) * 1989-03-06 1992-03-24 Trustees Of Boston University Method for therapeutically treating psoriatic arthritis using vitamin D analogues and metabolites
JP2831030B2 (ja) * 1989-05-12 1998-12-02 学校法人城西大学 ３’‐アジド‐３’デオキシチミジンを有効成分とする経皮投与製剤用組成物
US5021422A (en) * 1989-06-08 1991-06-04 Senetek Plc Method and composition for treating hyperproliferative skin diseases using 6-aminopurine cytokinins
US5162361A (en) * 1990-04-10 1992-11-10 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Method of treating diseases associated with elevated levels of interleukin 1
EP0663831A1 (en) * 1991-12-13 1995-07-26 G.D. Searle & Co. Transdermal azidothymidine
US5654286A (en) * 1993-05-12 1997-08-05 Hostetler; Karl Y. Nucleotides for topical treatment of psoriasis, and methods for using same
US5973010A (en) * 1998-05-15 1999-10-26 Crawford; Robert L. Composition for healing skin wounds
GR1003491B (el) * 1999-12-21 2000-11-30 Μεθοδος παρασκευης φαρμακοτεχνικου σκευασματος, αλοιφης η κρεμασκαι χρηση του στην αντιμετωπιση και θεραπεια της ψωριασεως και του εκζεματος
EP1998788A4 (en) * 2006-03-01 2011-08-03 Ruey J Yu COMPOSITIONS AND METHODS FOR THE TOPIC TREATMENT OF DERMATOLOGICAL DISORDERS RESPONSIBLE FOR TAR

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3650492T2 (de) * 1985-03-16 1996-10-31 The Wellcome Foundation Ltd., London Therapeutische Nukleoside
AU601556B2 (en) * 1987-03-16 1990-09-13 Wellcome Foundation Limited, The Therapeutic nucleosides

Also Published As

Publication number Publication date
JP2510675B2 (ja) 1996-06-26
EP0301206A2 (en) 1989-02-01
US4804651A (en) 1989-02-14
MY103734A (en) 1993-09-30
AU1751088A (en) 1988-12-15
DE3867560D1 (de) 1992-02-20
JPS6470417A (en) 1989-03-15
DK310188D0 (da) 1988-06-08
HUT47853A (en) 1989-04-28
IE881708L (en) 1988-12-09
HU200693B (en) 1990-08-28
PH26517A (en) 1992-08-07
ATE71301T1 (de) 1992-01-15
ES2038716T3 (es) 1995-04-01
EP0301206B1 (en) 1992-01-08
AU606423B2 (en) 1991-02-07
EP0301206A3 (en) 1989-09-06
DK310188A (da) 1988-12-12
GR3003785T3 (ko) 1993-03-16
IE61091B1 (en) 1994-09-21
KR950014447B1 (ko) 1995-11-28
ZA884056B (en) 1989-06-28

Similar Documents

Publication Publication Date Title
US4654373A (en) Pharmaceutical formulations containing coenzyme Q10 suitable for topic administration
PT1713490E (pt) Composições papa o tratamento da dermatite atópica,estados alérgicos da pele e acne.
US4256763A (en) Treatment of herpes simplex infections and acne
ES8500738A1 (es) Un procedimiento para la preparacion de una composicion antiinflamatoria topica como unguento en forma de gel
BR9814721A (pt) "uso de polióis, dispositivo apropriado para o tratamento ou profilaxia de infecção da mucosa causada por levedura em mamìferos, processo para tratamento terapêutico ou profilático de mamìferos sofrendo de ou sendo submetidos a um risco aumentado de infecção da mucosa causada por levedura, composição para uso neste trtatamento, e, preparação farmacêutica para uso no tratamento profilático ou terapêutico sistêmico ou tópico de infecções da mucosa causadas por levedura."
KR890000093A (ko) 건선의 치료방법 및 치료용 조성물
KR900017590A (ko) 좌창(Acne)치료방법 및 그 약제 조성물
US6093745A (en) Methods and composition for treating skin proliferative diseases
US3629412A (en) Topical anti-inflammatory agent
CS248712B2 (en) Production method of 6 alfa-methylcorticoids
Elic et al. Effect of salicylic acid on the activity of betamethasone-17, 21-dipropionate in the treatment of erythematous squamous dermatoses
Lassus Colloidal silicic acid for the treatment of psoriatic skin lesions, arthropathy and onychopathy. A pilot study
Günther Topical administration of vitamin A acid (retinoic acid) in palmar keratoses: callosities, hyperkeratotic eczema, hypertrophic lichen planus, pityriasis rubra pilaris
Lawrence et al. Effect of coal tar on cutaneous aryl hydrocarbon hydroxylase induction and anthralin irritancy
Brogden et al. Bufexamac: a review of its pharmacological properties and therapeutic efficacy in inflammatory dermatoses
JP4890250B2 (ja) 火傷した皮膚を治療するための方法及び組成物
KR960706345A (ko) 건선 치료(Psoriasis treatment)
EP1061802B1 (en) Topical carbamazepine formulations and methods of use
CA2330659A1 (en) Using ngali nut oil to treat/relieve manifestations of arthritis and other similar conditions
DE69906091T2 (de) Verwendung von lithium-gluconat zur herstellung eines arzneimittels zur behandlung von herpes und seborrhoischer dermatitis
Thompson Cream may reduce eczema relapse
Köse Calcipotriol ointment vs clobetasol solution in scalp psoriasis
EP0095512B1 (en) Antipsoriatic composition
ITMI950625A1 (it) Composizione farmaceutica attiva nella cura di affezioni dermatologiche
KR870005642A (ko) 디플루니살과 트로메타민의 혼합물

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
NORF Unpaid initial registration fee